JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
ADNOC Gas Targets Up to $4B Profit in 2026 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Merck KGaA, a leading pharmaceutical company based in Germany, announced that its experimental multiple sclerosis (MS) drug, evobrutinib, did not meet the primary goal in highly anticipated late-stage trials. The failure dealt a significant blow to the company's growth ambitions.
Trial Results and Comparison with Aubagio
Reuters reported that in the Phase III trials, evobrutinib failed to reduce the annualized relapse rate compared to Sanofi's Aubagio, a well-established drug for patients with relapsing MS. Merck, in a statement released on Tuesday, acknowledged this setback, as per Bloomberg.
Merck was seen as a frontrunner in a competitive race alongside Sanofi, Novartis, and Roche to develop more targeted MS drugs known as Bruton's tyrosine kinase (BTK) inhibitors. However, the result of this latest trial has cast a shadow over Merck's position in this space.
The MS drug category, including BTK inhibitors like evobrutinib, has raised concerns about a possible link to liver damage. While these drugs are designed to selectively block cells that drive the harmful autoimmune reaction behind MS, safety and efficacy remain crucial factors affecting revenue prospects for pharmaceutical companies.
Importance of Evobrutinib's Success for Merck
Merck's specialty materials businesses recently faced challenges due to weak demand. Analysts believed that the successful launch of evobrutinib could help the diversified group achieve its goal of generating 25 billion euros ($27 billion) in sales by 2025—an increase from 22.2 billion euros in 2022.
Merck's CEO, Belen Garijo, expressed confidence in evobrutinib, stating that the MS drug had the potential to achieve "blockbuster" status, referring to annual sales exceeding $1 billion. However, concerns about potential liver damage emerged, potentially impacting the drug's success.
In April, Merck faced a setback when U.S. regulators paused enrolling new patients into a trial testing evobrutinib, citing lab results suggesting drug-induced liver injury. Sanofi encountered similar challenges with its BTK drug candidate, tolebrutinib.
In trials, Novartis reported no signs of liver damage testing its anti-inflammatory drug candidate, remibrutinib. In a midstage trial, Roche revealed that fenebrutinib, their BTK inhibitor against MS, reduced harmful brain lesions without any new safety concerns.
The failed trials of evobrutinib mark another significant setback for Merck's medium-sized pharma unit. This follows the disappointing results of bintrafusp alfa, a cancer drug that failed in a 2021 trial, leading to the end of an alliance with GSK.
Photo: Merck Newsroom
